---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-103997"
form_type: "8-K"
ticker: "NMRA"
cik: "0001885522"
company_name: "Neumora Therapeutics, Inc."
filed_at: "2025-08-06T23:59:59+00:00"
generated_at: "2026-05-17T19:59:06.604898+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Neumora Q2 net loss $52.7M, cash $217.6M; advances NMRA-861 Phase 1, obesity lead for NMRA-215

## Summary
- Cash, equivalents and marketable securities of $217.6M as of June 30, 2025; expected to fund operations into 2027.
- Q2 net loss $52.7M vs $58.7M in Q2 2024; R&D expense fell to $38.7M from $48.6M.
- Initiated Phase 1 SAD/MAD study of M4 PAM NMRA-861; data expected Q1 2026.
- Prioritized obesity as lead indication for NLRP3 inhibitor NMRA-215; preclinical DIO data expected in 2025, clinical start Q1 2026.
- Expects up to six clinical data readouts over next 18 months including navacaprant Phase 3 (1H 2026) and NMRA-511 Phase 1b (end 2025).

## SEC filing metadata
- accession: 0000950170-25-103997
- form_type: 8-K
- ticker: NMRA
- cik: 0001885522
- company_name: Neumora Therapeutics, Inc.
- filed_at: 2025-08-06T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1885522/000095017025103997/0000950170-25-103997-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1885522/000095017025103997/nmra-20250806.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-103997
- JSON: https://secwatch.observer/filing/0000950170-25-103997.json
- Plain text: https://secwatch.observer/filing/0000950170-25-103997.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.